[1] WHO. Pocket Book of Hospital Care for Children. Guidelines for the Management of Common Illnesses with Limited Resources. 2005.
[2] WHO, Stop TB Partnership Childhood TB Subgroup. Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. Chapter 2: Anti-tuberculosis treatment in children. Int J Tuberc Lung Dis 10(11):1205–1211, 2006.
[3] Marais BJ et al. Childhood Pulmonary Tuberculosis. Old Wisdom and New Challenges.Am J Respir Crit Care Med Vol 173. pp 1078–1090, 2006.
[4] Blumberg HM et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med; 167:603–62, 2003.
[5] Donald PR, Seifart HI. Cerebrospinal fluid concentrations of ethionamide in children with tuberculous meningitis. J Pediatr;115:483–486, 1989.
[6] WHO, Stop TB Partnership Childhood TB Subgroup, Chapter 2, op cit.
[7] Nelson LJ, Wells CD. Global epidemiology of childhood tuberculosis. Int J Tuberc Lung Dis 8(5):636–647, 2004.
[8] Marais BJ et al. Childhood Pulmonary Tuberculosis. Old Wisdom and New Challenges.Am J Respir Crit Care Med Vol 173. pp 1078–1090, 2006.
[9] Schaaf et al. Recurrent culture-confirmed tuberculosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J ;24:685–691, 2005.
[10] Walters E et al. Clinical presentation and outcome of Tuberculosis in Human Immunodeficiency Virus infected children on anti-retroviral therapy. BMC Pediatrics 8:1, 1-12, 2008.
[11] Donald PR et al. Ethambutol dosage for the treatment of children: literature review and recommendations. Int J Tuberc Lung Dis; 10:1318–30, 2006.
[12] Schaaf HS et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child; 90:614–8, 2005.
[13] Graham SM et al. Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection. Antimicrob Agents Chemother 2006; 50:407–13.
[14] Donald PR, Schaaf HS. Old and new drugs for the treatment of tuberculosis in children. Paediatr Respir Rev; 8(2):134-41, 2007..
[15] Roy V, Tekur U, Chopra K. Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels. Indian Pediatr; 33: 287-291, 1996.
[16] Schaaf HS. Isoniazid Pharmacokinetics in Children Treated for Respiratory Tuberculosis." The Archives of Disease in Childhood; 90:614-618; 2005.
[17] Marais BJ et al. Diagnostic and Management Challenges for Childhood Tuberculosis in the Era of HIV. JID 196:S76–85, 2007.
[18] Schaaf HS, Shean K, Donald PR. Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome. Arch Dis Child;88:1106–1111, 2003.
[19] WHO. Considerations for infants and children coinfected with tuberculosis and HIV. In: Antiretroviral therapy of HIV in infants and children: towards universal access. Geneva: World Health Organization, 2006: 43–48.
[20] Puthanakit T et al. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected Thai children. Pediatr Infect Dis J; 25: 53–58; 2006.
[21] Walters, 2008. Op Cit.
[22] WHO, Stop TB Partnership Childhood TB Subgroup. Chapter 2, Op Cit.
[23] Walters, 2008. Op Cit.
[24] WHO, Stop TB Partnership Childhood TB Subgroup. Chapter 2, Op Cit.
[25] Hesseling AC et al. High Incidence of Tuberculosis among HIV-Infected Infants: Evidence from a South African Population-Based Study Highlights the Need for Improved Tuberculosis Control Strategies. Clinical Infectious Diseases; 48:108–14, 2009.
[26] Walters 2008, Op Cit.
[27] WHO, Stop TB Partnership Childhood TB Subgroup. Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. Management of TB in the HIV-infected child. Chapter 3. Int J Tuberc Lung Dis 10(12):1331–1336, 2006.
[28] Wiktor SZ et al. Efficacy of trimethoprim sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d’Ivoire: a randomised controlled trial. Lancet 353: 1469–75, 1999.
[29] Schaaf HS et al. Culture-confirmed childhood tuberculosis in Cape Town, South Africa: a review of 596 cases. BMC Infectious Diseases, 7:140, 2007.
[30] WHO, Stop TB Partnership Childhood TB Subgroup. Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. Chapter 4: Childhood contact screening and management. Int J Tuberc Lung Dis 11(1):12–15, 2007.
[31] Nyirenda M et al. Poor attendance at a child TB contact clinic in Malawi. Int J Tuberc Lung Dis 10(5):585–587, 2006.
[32] Esmonde TFG, Petheram IS. Audit of tuberculosis contact tracing procedures in South Gwent. Respir Med; 85: 421-424, 1991.
[33] Narian R et al. Distribution of tuberculous infection and disease among households in a rural community. Bull Wld health Organ 34: 639-654, 1966.
[34] Nunn P et al. The effect of human immunodeficiency virus type-1 on the infectiousness of tuberculosis. Tubercle Lung Dis 75: 25-32, 1994.
[35] Beyers N, Gie R P, Schaaf H S, et al. A prospective evaluation of children under the age of 5 years living in the same household as adults with recently diagnosed pulmonary tuberculosis. Int J Tuberc Lung Dis 1: 38–43, 1997.
[36] Nyirenda. Op cit.
[37] WHO, Stop TB Partnership Childhood TB Subgroup, Chapter 4. Op Cit.
[38] Zar HJ et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ 334;136, 2007.
[39] Madhi SA et al. Lack of efficacy of primary isoniazid (INH) prophylaxis in increasing tuberculosis (TB) free survival in HIV-infected (HIV+) South African children. 48th ICAAC, Washington. Abstract G2-1346a, 2008.
[40] Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis; 40: 670–76; 2005.
[41] Spyridis NP et al. The Effectiveness of a 9-Month Regimen of Isoniazid Alone versus 3- and 4-Month Regimens of Isoniazid plus Rifampin for Treatment of Latent Tuberculosis Infection in Children: Results of an 11-Year Randomized Study Clinical Infectious Diseases 45:715–22, 2007.
[42] Colditz G A, Brewer T F, Berkey C S, et al. Efficacy of BCG vaccine efficacy in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271: 698–702, 1994.
[43] Chokephaibulkit, K et al. Assessment of Bacille Calmette-Gue´rin Vaccine Reaction in HIV-Exposed Thai Infants. Clinical Infectious Diseases 45:1016–8; 2007.
[44] Hesseling AC et al. Danish strain BCG disease in HIV-infected infants. Int J Tuberculosis Lung Dis 9 (11, sup 1): S57, 2005.
[45] Hesseling AC et al. Danish Bacille Calmette-Guerin vaccine-induced disease in human immunodeficiency virus-infected children. Clin Inf Dis 37: 1226-1233, 2003.
[46] Hesseling AC et al. The risk of disseminated bacille Calmette-Guérin (BCG) disease in HIV-infected children. Vaccine; 25: 14–18, 2007.
[47] Fallo A et al. Delayed complications of bacillus Calmette-Guérin (BCG) vaccination in HIV-infected children. International AIDS Society Conference, Rio de Janeiro, Brazil, 2005.
[48] Talbot EA et al. Disseminated vaccination: case report and review. Clin Infect Dis 1997; 24: 1139–1146.
[49] World Health Organization. Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly Epidemiol Rec 82: 193–196, 2007.
[50] Hesseling AC et al. Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. Int J Tuberc Lung Dis 12(12):1376–1379, 2007.
[51] Ibid.
[52] Rabie H, Violari A, Madhi S, et al. Complications of BCG vaccination in HIV-infected and -uninfected children: (Children with HIV Early Antiretroivral Therapy) CHER Study. 15th CROI, Boston, 2008.
[53] Walters, Op cit.
[54] Hesseling, 2009. Op cit.
[55] Burman WJ et al. (2008) Assuring the involvement of children in the evaluation of new tuberculosis treatment regimens. PLoS Med 5(8): e176, 2008..